Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nuscale Power Corporation (SMR) vs Twist Bioscience Corp (TWST) Price & Performance

Nuscale Power CorporationTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Nuscale Power Corporation vs Twist Bioscience Corp — how do they compare? Nuscale Power Corporation trades at $7.2 (market cap $3.00B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 3.4× Nuscale Power Corporation's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuscale Power Corporation for 29 Days and Twist Bioscience Corp for 27 Days on average.

SMRTWST
Market Cap
$3.00B$10.08B
Volume
43,143,1094,229,037
Sector
IndustrialsHealth
52-Week High
$53.43$205.00
52-Week Low
$7.20$25.45
Typical Hold Time
29 Days27 Days
Enterprise Value
$1.93B$10.01B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nuscale Power Corporation

NuScale Power (SMR) trades at $7.32, down 4.56% with bearish technical signals. The company shows concerning fundamentals with negative net income margin of -3,888.7% and declining revenue from $31.48M in 2025 to $11M in 2026. Despite operating cash burn, financing activities provided $1.31B in 2025. Analyst consensus is mixed with 50% buy ratings but ongoing SEC investigation concerns.

The stock faces significant execution risk in commercializing SMR technology amid cash burn and competitive pressure. Upside exists if NuScale achieves commercialization milestones, with analyst targets up to $16. However, current financial performance and negative margins present substantial risk for investors seeking near-term returns.

Twist Bioscience Corp

TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.

Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SMR
79% Buy21% Sell
Avg holding period · 29 Days
TWST
100% Buy0% Sell
Avg holding period · 27 Days

Top news

Latest headlines on both assets

About Nuscale Power Corporation

NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.

Read more on SMR →

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST →